| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15d42f684941d5b0617ca7764ebdff07 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a16fea08441e8793083494294fabe88b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99f575e875c91ca9292ff39772b160a6 |
| publicationDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018230490-A1 |
| titleOfInvention |
Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| abstract |
This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11198873-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11542506-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10584337-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023288086-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10597660-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10570395-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11193129-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434502-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10920227-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11603542-B2 |
| priorityDate |
2006-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |